I just read the report and from having followed RVX for 8 years I am aware of most of the material. BDAZ provides all of us with excellent understanding with what this company is achieving and they (the RVX scientists) are remarkable.

From a stock valuation perspective I do feel the report does not provide enough of a framework for where a stock should be valued in a phase 3 trial although there is chart that illustrates the probablilities of success vs a phase 2 trial.

Nothing new but it is written in a language that people like me can understand and I must say it re-energized my belief not just in apabetalone (rvx-208) but also in the fundamental science that this company has developed a huge and leading knowledge base in.

From a share price perspective I wish that the people at RVX new how to leverage this report but I don't think that will happen.

Anyway, great to see the report and I suggest everyone read it. It is an easy read and sure inspires me to keep faith in the RVX science.

Toinv